L3VLUP
ProSign in

BHC · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BHCVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BHC
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterBHCVRTX
Q3 202010 holders, $664m31 holders, $21.9bn
Q4 202011 holders, $1.0bn30 holders, $18.4bn
Q1 202112 holders, $2.3bn31 holders, $15.4bn
Q2 202114 holders, $2.2bn30 holders, $12.7bn
Q3 202110 holders, $2.0bn35 holders, $10.1bn
Q4 20219 holders, $1.8bn28 holders, $12.4bn
Q1 202213 holders, $1.5bn23 holders, $16.1bn
Q2 20228 holders, $539m25 holders, $18.1bn
Q3 202210 holders, $350m22 holders, $18.4bn
Q4 20229 holders, $325m28 holders, $18.4bn
Q1 20235 holders, $387m26 holders, $21.4bn
Q2 20236 holders, $409m27 holders, $24.7bn
Q3 20239 holders, $429m33 holders, $24.3bn
Q4 20236 holders, $403m32 holders, $28.6bn
Q1 20249 holders, $594m31 holders, $29.8bn
Q2 20248 holders, $380m29 holders, $33.4bn
Q3 20246 holders, $331m27 holders, $33.5bn
Q4 20246 holders, $341m26 holders, $28.5bn
Q1 20255 holders, $277m21 holders, $35.4bn
Q2 20255 holders, $285m21 holders, $32.3bn
Q3 20254 holders, $47m22 holders, $25.9bn
Q4 20256 holders, $68m26 holders, $31.8bn
Q1 20265 holders, $61m25 holders, $31.8bn
Q2 20264 holders, $55m26 holders, $34.6bn
BHC

Bausch Health Cos Inc

Holders
4
Reported value
$47m
Buyers
1
Sellers
2

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BHC (3)

GAMCO Investors Inc, Oaktree Capital Management LP, Third Point LLC

Only VRTX (21)

AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →